Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022Business Wire • 01/19/22
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual RuleBusiness Wire • 01/15/22
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali TehraniBusiness Wire • 01/05/22
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone PaymentBusiness Wire • 12/09/21
Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast CancerBusiness Wire • 12/08/21
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic PlatformsBusiness Wire • 12/01/21
Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)Business Wire • 11/19/21
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)Business Wire • 11/09/21
Will Zymeworks Inc. (ZYME) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/26/21
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal CancersBusiness Wire • 10/26/21
Here's Why Zymeworks Inc. (ZYME) is Poised for a Turnaround After Losing 24.1% in 4 WeeksZacks Investment Research • 10/11/21
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid TumorsBusiness Wire • 10/05/21
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual CongressBusiness Wire • 09/16/21
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual CongressBusiness Wire • 09/12/21
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks' Azymetric™ and EFECT™ Therapeutic PlatformsBusiness Wire • 08/03/21
Earnings Preview: Zymeworks Inc. (ZYME) Q2 Earnings Expected to DeclineZacks Investment Research • 07/28/21